Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

DPP-IV Inhibitors Markets 2016-2024 - Global Strategic Business Report 2018 - ResearchAndMarkets.com

Research and Markets
Posted on: 19 Oct 18

The "DPP-IV Inhibitors - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets for DPP-IV Inhibitors in US$ Million.

The Global market is analyzed by the following Drugs:

  • Sitagliptin
  • Vildagliptin
  • Saxagliptin
  • Others

The US market is further analysed in terms of sales by the following drug Segments:

  • Sitagliptin
  • Saxagliptin
  • Linagliptin
  • Alogliptin

The report profiles 14 companies including many key and niche players such as:

  • AstraZeneca Plc. (UK)
  • Boehringer Ingelheim GmbH (Germany)
  • Eli Lilly and Company (USA)
  • Merck & Co, Inc. (USA)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)

Key Topics Covered:

1. Introduction, Methodology & Product Definitions

2. Industry Overview

3. The Diabetes Epidemic

4. An Overview Of Drug Classes In Anti-Diabetic Drugs Category

5. A Review Of Select Approved DPP-IV Inhibitor Drugs

6. DPP-IV Inhibitors - An Overview Of The Drug Class

7. Competitive Landscape

8. Global Market Perspective

9. Regional Market Perspective

10. Company Profiles

Total Companies Profiled: 14 The United States (2)

  • Japan (6)
  • Europe (3)
    • Germany (1)
    • The United Kingdom (1)
    • Rest of Europe (1)
  • Asia-Pacific (Excluding Japan) (3)

For more information about this report visit https://www.researchandmarkets.com/research/dk699k/dppiv_inhibitors?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005466/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.